```html

Malaignant Hyperthermia

What is Malaignant Hyperthermia?

Malaignant hyperthermia (MH) is a rare, life‑threatening pharmacogenetic disorder that causes a rapid rise in body temperature and severe muscle rigidity after exposure to certain anesthetic agents or trigger drugs. It is not an infection or fever caused by illness; instead, it results from an abnormal release of calcium inside skeletal muscle cells, leading to sustained muscle contraction, hypermetabolism, and a cascade of systemic effects.

The condition can develop within minutes of exposure to triggering agents and, if untreated, may progress to cardiac arrest, renal failure, or death. Prompt recognition and treatment with the antidote dantrolene are crucial for survival.

Sources: Mayo Clinic, Cleveland Clinic, National Institute of General Medical Sciences (NIGMS).

Common Causes

MH is triggered primarily by certain drugs used during general anesthesia, but other factors can predispose or unmask the disorder. Below are the most frequently reported causes and contributors.

• Inhalational anesthetics – e.g., sevoflurane, desflurane, isoflurane, halothane.
• Depolarizing muscle relaxants – most notably succinylcholine.
• Non‑depolarizing muscle relaxants – rarely, in patients with a pre‑existing susceptibility.
• Genetic mutations – primarily in the RYR1 gene (ryanodine receptor) and, less commonly, in CACNA1S.
• Stressful surgical procedures – high‑intensity surgeries can increase metabolic demand.
• Extreme exertion or heat exposure – in individuals carrying a susceptibility gene, intense exercise or hot environments may precipitate a milder “awake” MH‑like episode.
• Temperature‑raising medications – certain anticholinergics or sympathomimetics can aggravate hyperthermia in predisposed patients.
• Electrolyte disturbances – severe hyperkalemia or hypocalcemia may lower the threshold for an MH reaction.
• Pre‑existing neuromuscular disorders – such as central core disease or multiminicore disease, which share the same genetic pathways.
• Familial predisposition – a first‑degree relative with a documented MH event dramatically increases risk.

Associated Symptoms

When MH is triggered, a characteristic pattern of signs emerges. Not every symptom appears in every patient, but the following are the most common clinical features:

• Rapid increase in core body temperature – often > 38.5 °C (101 °F) and may exceed 42 °C (107.6 °F) within minutes.
• Generalized muscle rigidity – especially of the jaw (masseter spasm), neck, and limbs.
• Accelerated heart rate (tachycardia) – may exceed 120 bpm.
• Elevated carbon dioxide production – evidenced by rising end‑tidal CO₂ (EtCO₂) despite increased ventilation.
• Acidosis – metabolic and respiratory, reflected in low blood pH and high serum lactate.
• Hyperkalemia – release of intracellular potassium from contracting muscles.
• Myoglobinuria – dark‑colored urine due to muscle breakdown (rhabdomyolysis).
• Arrhythmias – ventricular tachycardia or fibrillation may develop.
• Coagulopathy – disseminated intravascular coagulation (DIC) in severe cases.
• Renal impairment – secondary to myoglobin precipitation in the kidneys.

These manifestations often develop in a cascading fashion, making early detection essential.

When to See a Doctor

Because MH usually occurs in the operating room, the primary care setting for detection is intra‑operative monitoring. However, patients with a known genetic susceptibility can experience “awake” episodes. Seek immediate medical attention if you or a family member experiences any of the following after surgery, anesthesia, or intense physical activity:

• Sudden, unexplained high fever (> 39 °C/102 °F) that does not respond to standard antipyretics.
• Severe muscle stiffness or painful cramps, especially of the jaw or neck.
• Rapid heartbeat, shortness of breath, or feeling “flushed” without an obvious cause.
• Dark urine (brown or tea‑colored) indicating possible rhabdomyolysis.
• Unexplained dizziness, confusion, or loss of consciousness during or after a procedure.
• Any known family history of MH or a previous reaction to anesthesia.

If you suspect an episode, call emergency services (911 in the United States) while alerting the responders that the person may have malignant hyperthermia.

Diagnosis

Diagnosis of MH is a combination of clinical suspicion, laboratory testing, and specialized genetic or functional studies.

During an Acute Episode

1. Clinical monitoring – rapid rise in EtCO₂, heart rate, and temperature.
2. Blood gas analysis – shows metabolic acidosis (low pH, low HCO₃⁻) and elevated lactate.
3. Serum electrolytes – hyperkalemia, hyperphosphatemia.
4. Creatine kinase (CK) – markedly elevated (> 1000 U/L) indicating muscle breakdown.
5. Myoglobin in urine – positive dipstick or spectrophotometric testing.

After Stabilization

• Caffeine‑Halothane Contracture Test (CHCT) – the gold‑standard functional test performed on a muscle biopsy to assess abnormal contracture response.
• Genetic testing – sequencing of RYR1 and CACNA1S genes; identifies pathogenic variants in up to 50 % of cases.
• Family screening – cascade testing of first‑degree relatives when a mutation is identified.

Reference: American Society of Anesthesiologists (ASA) Practice Guidelines for Malignant Hyperthermia (2022).

Treatment Options

Time is critical. The treatment algorithm focuses on stopping the trigger, reversing the metabolic crisis, and supporting organ function.

Immediate Hospital Management

1. Discontinue triggering agents – switch to a non‑triggering anesthetic (e.g., total intravenous anesthesia with propofol).
2. Administer dantrolene sodium – initial dose 2.5 mg/kg IV; repeat every 5 minutes until signs abate, up to a total of 10 mg/kg. Dantrolene directly reduces uncontrolled calcium release from the sarcoplasmic reticulum.
3. Active cooling – ice packs, cooling blankets, cold intravenous fluids, and, if necessary, intravascular cooling devices.
4. Hyperventilation with 100 % O₂ – to wash out CO₂ and correct hypoxia.
5. Correct metabolic derangements –
   • IV sodium bicarbonate for acidosis.
   • Calcium chloride/gluconate if severe hyperkalemia or cardiac instability.
   • Insulin‑glucose infusion to drive potassium intracellularly.
6. Fluid resuscitation – large‑volume crystalloids to maintain renal perfusion and dilute myoglobin.
7. Urine alkalinization – sodium bicarbonate infusion + mannitol to prevent renal tubular obstruction.
8. Monitoring – continuous ECG, arterial line for blood pressure, core temperature probe, and serial labs (CK, electrolytes, renal function).

Post‑Acute Care

• Observation in an intensive‑care unit for at least 24 hours after symptom resolution.
• Repeat CK and renal labs daily until trends normalize.
• Physical therapy if prolonged muscle weakness occurred.
• Psychological support for patients and families, especially after a traumatic event.

Home & Long‑Term Management

• Carry a medical alert bracelet or necklace indicating MH susceptibility.
• Maintain a personal “MH emergency card” that lists known triggers and the required dose of dantrolene.
• Avoid known triggering anesthetics; inform every healthcare provider before any procedure.
• Regular follow‑up with a neurologist or anesthesiologist familiar with MH.

Prevention Tips

While it is impossible to prevent a genetic predisposition, several practical steps can dramatically reduce risk:

• Pre‑operative screening – thorough family history and, when indicated, genetic testing before elective surgery.
• Use of non‑triggering anesthetic protocols – total intravenous anesthesia (TIVA) with agents such as propofol, dexmedetomidine, and non‑depolarizing muscle relaxants.
• Availability of dantrolene – all hospitals and ambulatory surgical centers must stock at least 36 vials (the recommended minimum) and have a rapid dispensing system.
• Education of patients and families – provide written information about MH, trigger avoidance, and emergency actions.
• Temperature management – ensure operating rooms are kept at appropriate ambient temperatures and use warming devices only when necessary.
• Exercise caution with “awake” triggers – individuals with a known mutation should avoid extreme heat exposure, strenuous exercise in hot climates, and certain over‑the‑counter medications that may increase calcium release.

Emergency Warning Signs

---

Malignant hyperthermia is a medical emergency that demands swift recognition and treatment. Understanding the triggers, early signs, and preventive strategies can save lives. If you or a loved one has a personal or family history of MH, discuss an anesthetic plan with your surgeon and anesthesiologist well before any procedure.

References:

1. Mayo Clinic. “Malignant Hyperthermia.” Updated 2023. https://www.mayoclinic.org
2. Cleveland Clinic. “Malignant Hyperthermia.” 2022. https://my.clevelandclinic.org
3. American Society of Anesthesiologists. “Practice Guidelines for Malignant Hyperthermia.” 2022.
4. National Institute of General Medical Sciences. “Malignant Hyperthermia.” 2021. https://www.nigms.nih.gov
5. World Health Organization. “Safety in Anesthesia.” WHO Guidelines, 2020.

```